Clinical Trial Update: Naltrexone for Impulse Control Disorders in Parkinson's Disease [Phase 4]

View source ↗

Summary

This document reports the completion of a Phase 4 trial evaluating naltrexone for impulse control disorders in Parkinson's disease, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impulse Control Disorders
• Parkinson Disease

Drugs mentioned

• Naltrexone (Naltrexone)

Snippet

Sponsor: University of Pennsylvania | Conditions: Impulse Control Disorder, Parkinson Disease | Phase 4 | Status: COMPLETED | Results posted: 2015-06-22